Ikonisys Completes Capital Increase to Boost Commercial Expansion

Paris, June 3, 2024 – Ikonisys SA, a company specializing in automated cancer detection solutions, has raised €150k through a private placement. This capital increase aims to enhance the company's financial stability and accelerate its development.

The new funds will support commercial growth by financing working capital needs and extending financial visibility. They also facilitate the integration of Hospitex and expansion of offerings in Europe, with plans for the USA at a later stage.

The Board of Directors approved the capital increase on May 30, 2024. Issuing 100,000 new shares at €1.5 each, the process relied on the 8th resolution from the June 2023 shareholders' meeting and did not require AMF approval.

With the secured financing, Ikonisys can meet its financial commitments for over 12 months. The new share issuance only slightly impacts existing shareholders, reducing a 1% holding to 0.99% on a non-diluted basis.